Thyroid Eye Disease Clinical Trials

9 recruiting

Thyroid Eye Disease Trials at a Glance

13 actively recruiting trials for thyroid eye disease are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in Morgantown, Shanghai, and Beijing. Lead sponsors running thyroid eye disease studies include Minghui Pharmaceutical (Hangzhou) Ltd, Peking University Third Hospital, and Imperial College London.

Browse thyroid eye disease trials by phase

Treatments under study

About Thyroid Eye Disease Clinical Trials

Looking for clinical trials for Thyroid Eye Disease? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid Eye Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid Eye Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen88 enrolled30 locationsNCT06401044
Recruiting
Phase 3

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd258 enrolled1 locationNCT07262476
Recruiting
Phase 3

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd150 enrolled1 locationNCT07257185
Recruiting

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

AsthmaVasculitisInflammatory Disease+2 more
Imperial College London120 enrolled1 locationNCT05012033
Recruiting
Not Applicable

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

Thyroid Eye Disease
Peking University Third Hospital50 enrolled1 locationNCT07423013
Recruiting
Phase 1

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

SafetyTolerabilityGenSci098+1 more
Changchun GeneScience Pharmaceutical Co., Ltd.76 enrolled1 locationNCT06569758
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Thyroid Eye Disease
Tourmaline Bio, Inc.81 enrolled56 locationsNCT06088979
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Thyroid Eye Disease (TED)
Zai Lab (Shanghai) Co., Ltd.99 enrolled27 locationsNCT07211776
Recruiting
Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

Thyroid Eye Disease
Innovent Biologics (Suzhou) Co. Ltd.111 enrolled1 locationNCT07113262
Recruiting
Phase 2Phase 3

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid DiseasesEndocrine System DiseasesThyroid Eye Disease+9 more
Sling Therapeutics, Inc.75 enrolled2 locationsNCT06112340
Recruiting

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Thyroid Eye DiseaseOrbitopathy, GravesOphthalmopathy
Medical University of Warsaw30 enrolled1 locationNCT06367517
Recruiting
Not Applicable

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

Thyroid Eye Disease
Peking University Third Hospital50 enrolled1 locationNCT06359795
Recruiting

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Graves DiseaseThyroid Eye DiseaseGraves Ophthalmopathy
Walter Reed National Military Medical Center100 enrolled1 locationNCT06275373